A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania

BACKGROUND: In the European Union, a tablet with fixed doses of ombitasvir, paritaprevir, and ritonavir combined with dasabuvir is an authorized treatment for patients with chronic hepatitis C virus (HCV) infection. Ribavirin is a broad-spectrum antiviral used in several treatment regimens for patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Bacinschi, Xenia, Popescu, Gabriel Cristian, Zgura, Anca, Gales, Laurentia, Rodica, Anghel, Mercan, Adriana, Serban, Dragos, Haineala, Bogdan, Toma, Letitia, Iliescu, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270854/
https://www.ncbi.nlm.nih.gov/pubmed/35787600
http://dx.doi.org/10.12659/MSM.936706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270854/
https://www.ncbi.nlm.nih.gov/pubmed/35787600
http://dx.doi.org/10.12659/MSM.936706

Ejemplares similares